Evidence map›Paper›PMID 30132031›Full record

ReviewDiabetologia2018

Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits.

Beatrice C Lupsa, Silvio E Inzucchi

Open access · bronzeAbstract readReview
PubMed Publisher
In one paragraph

Review in Diabetologia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
88citing papers in PubMed, 8 pooled it
14.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

88 citing papers in PubMed, 8 syntheses or guidelines pooled it, 186 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Glucocorticoid-Induced Hyperglycemia Including Dexamethasone-Associated Hyperglycemia in COVID-19 Infection: A Systematic Review.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2022
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Role of sodium-glucose cotransporter 2 inhibitors in liver diseases.World journal of experimental medicine · 2025
    Review
  17. Review
  18. Review
  19. Review
  20. Article

28 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Beatrice C LupsaSection of Endocrinology, Yale University School of Medicine, Yale-New Haven Hospital, 333 Cedar Street, FMP 106, P.O. Box 208020, New Haven, CT, 06520, USA.
Silvio E InzucchiSection of Endocrinology, Yale University School of Medicine, Yale-New Haven Hospital, 333 Cedar Street, FMP 106, P.O. Box 208020, New Haven, CT, 06520, USA. silvio.inzucchi@yale.edu.
Yale University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sodium-glucose cotransporter 2 (SGLT2) inhibitors belong to a novel class of glucose-lowering medications that reduce plasma glucose concentrations by inhibiting glucose reabsorption by the kidney, inducing glucosuria. Their actions encompass reductions in HbA

Indexed as

Benzhydryl CompoundsBlood GlucoseBlood PressureBody WeightBone and BonesCanagliflozinCardiovascular DiseasesDiabetes Mellitus, Type 2Diabetic KetoacidosisGlucosidesHumansHypoglycemic AgentsKetosisKidneyNeoplasmsRandomized Controlled Trials as TopicBenzhydryl CompoundsBlood GlucoseCanagliflozinempagliflozinGlucosidesHypoglycemic AgentsSLC5A2 protein, humanSodium-Glucose Transporter 2Sodium-Glucose Transporter 2 InhibitorsBenefitsCardiovascularFracturesKetoacidosisRenalReviewRisksSGLT2 inhibitorsType 2 diabetes

Identifiers

PMID30132031
OpenAlexW2883001358

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.